RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (Australia), Commissioner's National Priority Voucher (United States)

Structure/Sequence

Sequence Code 28791467

Source: *****

Clinical Trials associated with Cenegermin-BKBJ

NCT06411145

/ WithdrawnPhase 4

A Prospective, Multicenter Trial to Evaluate Efficacy and Safety of Cenegermin-bkbj (20 mcg/mL) Ophthalmic Solution on Corneal Thickness Via Anterior Segment Optical Coherence Tomography (AS-OCT) in Stage 3 Neurotrophic Keratitis

Primary Objective:
To assess the efficacy of cenegermin-bkbj (20 mcg/mL) ophthalmic solution on overall corneal thickness via AS-OCT in patients with stage 3 neurotrophic keratitis with respect to change from baseline at weeks 4, 8, and 16.
Secondary Objectives:
To assess the effects of cenegermin-bkbj (20 mcg/mL) ophthalmic solution on corneal stromal thickness via AS-OCT in patients with stage 3 neurotrophic keratitis with respect to change from baseline at weeks 4, 8, and 16.
To assess the effects of cenegermin-bkbj (20 mcg/mL) ophthalmic solution on corneal stromal reflectivity via AS-OCT in patients with stage 3 neurotrophic keratitis with respect to change from baseline at weeks 4, 8, and 16.
To assess the effects of cenegermin-bkbj (20 mcg/mL) ophthalmic solution on corneal sensitivity via Cochet-Bonnet aesthesiometer in the center of the lesion with respect to change from baseline at weeks 4, 8, and 16.

Start Date26 Apr 2024

Sponsor / Collaborator

Dompe Farmaceutici SpA

NCT06244316

/ CompletedPhase 2

A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study With 4 Weeks of Follow-Up to Evaluate Safety and Efficacy of a New Formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution at Two Different Concentrations in Patients With Dry Eye Disease

The purpose of this study is to evaluate the safety and efficacy of two different concentrations of the new formulation of rhNGF ophthalmic solution versus vehicle, in order to demonstrate superiority of at least one of the two concentrations over vehicle in the improvement of ocular symptoms of dry eye in participants with dry eye disease (DED). The rhNGF ophthalmic solution, or vehicle, will be administered as one drop in each eye, three times a day, for 4 weeks. Participants will attend a total of 5 study visits from screening through end of the study (Week 8), which will include eye exams and questionnaires.

Start Date22 Jan 2024

Sponsor / Collaborator

Dompe Farmaceutici SpA

NCT05552261

/ CompletedNot Applicable

A Long-term Extension Study to Evaluate the Safety and Efficacy of OXERVATE® 0.002% (20 mcg/mL) Cenegermin-bkbj Ophthalmic Solution in Patients With Stage 1 Neurotrophic Keratitis Who Enrolled in the DEFENDO Study (NGF0120)

Primary Objective
To evaluate the long-term safety and efficacy (healing) of OXERVATE® 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in Stage 1 neurotrophic keratitis (NK) patients who enrolled in the DEFENDO study.
Secondary Objective
To evaluate the long-term efficacy of OXERVATE® 0.002% (20 mcg/mL) cenergemin-bkbj ophthalmic solution in terms of corneal sensitivity, Schirmer I test, tear film break-up time (TFBUT), best corrected distance visual acuity (BCDVA), and quality of life at 24 and 30 months post-treatment

Start Date01 Feb 2023

Sponsor / Collaborator

Dompe Farmaceutici SpA

100 Clinical Results associated with Cenegermin-BKBJ

100 Translational Medicine associated with Cenegermin-BKBJ

100 Patents (Medical) associated with Cenegermin-BKBJ

168

Literatures (Medical) associated with Cenegermin-BKBJ

01 Dec 2025·Ophthalmology and Therapy

Cenegermin for the Treatment of Moderate or Severe Neurotrophic Keratopathy: Results from a Prospective, Phase IV, Open-Label Study in China

Article

Author: Li, Suxia ; Siri, Giacomo ; Xu, Jianjiang ; Shi, Weiyun ; Yuan, Jin ; Pan, Zhiqiang ; Hauswirth, Scott G ; Mantelli, Flavio

INTRODUCTION:

Neurotrophic keratopathy (NK) is a rare degenerative disease that can lead to epithelial breakdown, corneal ulceration, and potentially perforation and vision loss. Cenegermin is a recombinant human nerve growth factor approved for stage 2/3 NK, though data on its efficacy outside of United States/European populations are limited.

METHODS:

This prospective, phase IV, open-label, multicenter study investigated the efficacy, safety, and pharmacokinetics (PK) of cenegermin eye drops in Chinese patients with stage 2/3 NK in a routine clinical setting (CTR20220066). Patients received cenegermin eye drops (20 mcg/mL; 6 times/day at 2-hour intervals) for 8 weeks with follow-up to week 56. The primary endpoint was corneal healing at week 8 per investigator assessment. Additional endpoints included lesion worsening, corneal healing through week 56, safety, and PK.

RESULTS:

Of the 28 patients receiving cenegermin, 22/26 (84.6%, 95% confidence interval 65.1-95.6%; 2 missing) achieved corneal healing at week 8; 3/22 (13.6%) reported recurrence during 48-week follow-up but 20/22 (90.9%) were healed at week 56; and 2/28 (7.1%) experienced lesion worsening during 8-week treatment. In addition, 25/28 (89.3%) experienced ≥ 1 treatment-emergent adverse event (TEAE); for the majority (23/28, 82.2%) of these patients, TEAEs were mild/moderate. None of the serious TEAEs reported by 10 (35.7%) patients were assessed as related to cenegermin or led to treatment discontinuation. Eye pain was the most common cenegermin-related TEAE (5/28, 17.9%), primarily limited to the treatment period.

CONCLUSIONS:

These findings demonstrate that cenegermin eye drops are an effective, generally well-tolerated treatment in Chinese patients with stage 2/3 NK, supporting their use in this patient population.

TRIAL REGISTRATION:

CTR20220066.

01 Dec 2025·EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Safety and pharmacokinetics of escalating doses of recombinant human nerve growth factor eye drops (HT006.2.2) in healthy subjects

Article

Author: Hu, Xiaojun ; Ni, Siyang ; Lu, Laichun ; Jie, Ying ; Lu, Huan ; Pang, Hongyan ; Tang, Huadong ; Wu, Feng ; Yu, Wei ; Dai, Yuyang ; Jiao, Ying ; Han, Ying

BACKGROUND:

HT006.2.2 is a kind of recombinant human nerve growth factor (rhNGF) eye drop with the potential to treat neurotrophic keratitis.

OBJECTIVE:

To evaluate the safety, immunogenicity, and pharmacokinetic (PK) characteristics of HT006.2.2 eye drops in Chinese healthy volunteers.

METHODS:

This study was divided into three parts. In Part A (single-dose) and Part B (multi-dose), four dose groups were per-specified: 5 µg/mL, 20 µg/mL, 60 µg/mL and 120 µg/mL. Each dose group comprised eight subjects randomized in a 3:1 ratio to receive the HT006.2.2 or placebo. Serum samples were collected for systemic PK analysis and anti-drug antibody (ADA) detection. The Part C comprised two single-dose groups (20 µg/mL and 60 µg/mL), and tear samples were collected at preset time points for tear fluid PK analysis. The drug mass per gram of tears (unit: µg/g) was calculated and used as the drug concentration to recalculate the PK parameters. Safety was evaluated via vital signs monitoring, 12-lead electrocardiogram, clinical laboratory tests, and ophthalmologic assessments (ocular symptoms and signs, slit-lamp microscopy, corneal fluorescein sodium staining, intraocular pressure measurement, and best-corrected visual acuity). Adverse events were collected following the initial administration of the investigational drug and were defined as treatment-emergent adverse events (TEAEs).

RESULTS:

This study enrolled a total of 163 subjects, with 161 receiving the medication and completing the study as planned. HT006.2.2 showed favorable tolerance across both single-dose and multiple-dose parts. At the highest dose of 120 µg/mL, no maximum tolerated dose (MTD) was reached. No discernible dose-response relationship was identified in the incidence of TEAEs across dosage groups, with the total TEAE rate in HT006.2.2 groups remaining non-exceeding that of the placebo group. Ocular TEAEs included corneal vital dye staining, eye itching, eye pain, conjunctival hyperemia, and decreased visual acuity. In addition, no HT006.2.2 or ADA was detected in the peripheral blood of healthy subjects. Tear fluid PK analysis of HT006.2.2 (20 µg/mL) showed time to peak concentration (T_max) of 0.17 h, mean peak concentration (C_max) of 3.63 ± 2.06 µg/g, elimination half-life (t_1/2) of 4.21 h.

CONCLUSIONS:

HT006.2.2 eye drops exhibited favorable safety in Chinese healthy subjects, with localized ocular distribution, no systemic exposure, and no detectable ADAs. These findings support the continuation of clinical development for HT006.2.2 in China.

01 Oct 2025·Ocular Surface

Prospective consecutive case series of patients with neurotrophic keratopathy associated with unilateral total limbal stem cell deficiency caused by severe ocular surface burns

Article

Author: Figueiredo, Francisco C ; Mudhar, Hardeep-Singh ; Lako, Majlinda ; Stefanache, Teodor ; Baylis, Oliver J ; Figueiredo, Gustavo S

INTRODUCTION:

Limbal stem cell deficiency (LSCD) is commonly caused by ocular surface burns. Corneal nerve damage, often due to infection, inflammation, trauma, leads to neurotrophic keratopathy (NK). This study investigates corneal sensation and nerve damage in patients with unilateral total LSCD before and after autologous cultivated limbal epithelial transplantation (Auto-CLET).

METHODS:

This prospective, single-centre case series included patients with unilateral total LSCD due to severe burns treated at Royal Victoria Infirmary, UK, between June 2012 and January 2018. Corneal sensation was assessed using Cochet-Bonnet aesthesiometry at baseline and 6 months post-Auto-CLET, and in vivo confocal microscopy (IVCM) was used to examine nerve regeneration.

RESULTS:

Twenty-three patients (19 males, 4 females) received Auto-CLET. Successful restoration of the ocular surface was achieved in all patients, confirmed by slit lamp examination, impression cytology, and IVCM at follow-ups up to 36 months. Baseline best corrected visual acuity was 1.67 logMAR in the affected eye compared to a mean of -0.08 in the healthy eye. Corneal aesthesiometry in LSCD eyes averaged 9.13 mm at baseline, increasing to 12.0 mm at 6 months post-Auto-CLET, though this change was not statistically significant (p = 0.26). IVCM revealed no regeneration of corneal nerves at any follow-up intervals, indicating persistent nerve damage.

CONCLUSIONS:

Despite successful ocular surface restoration, corneal nerve damage persisted, leaving patients at risk of persistent NK. To address this, we strongly suggest continuous topical treatment with blood derived products, such as serum eye drops, but also newly developed therapies such as IGF and rhNGF class of drugs.

News (Medical) associated with Cenegermin-BKBJ

20 Oct 2025

·www.pharmaceutical-technology.com

Infertility treatment heads first drugs on FDA’s new priority review scheme

Pharma companies wishing to reap the benefits of the programme need to demonstrate US-centric potential for their drug candidates. kemalbas via GettyImages. The US Food and Drug Administration (FDA) has selected the first products to be included on the Commissioner’s National Priority Voucher (CNPV) pilot programme. A total of nine drug candidates have joined the scheme launched in June 2025 , which will see its developers receive a voucher that will significantly expedite their path to approval. The group is headed by Merck’s Pergoveris (follitropin alfa/lutropin alfa), which is already approved in Europe, for the treatment of infertility. President Donald Trump specifically identified Pergoveris’ inclusion, touting the drug’s potential to offer a cheaper option to US patients. “This drug would directly compete against a much more expensive option that currently has a monopoly in the American market, and this will bring down costs very significantly,” Trump said during an IVF news conference at the White House. Trump was likely referring to Gonal-f, made by Merck’s US and Canadian healthcare business EMD Serono. Gonal-f generated global sales of €833m in 2024. The pharma company plans to use its CNPV to file for FDA approval of its new drug, which it disclosed while announcing a broader deal with the US government to expand fertility access treatment. Elsewhere on the list, candidates being developed for hearing and vision loss have been included in the form of Regeneron’s gene therapy DB-OTO and Dompé Farmaceutici’s Oxervate (cenegermin-bkbj), respectively. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence Sanofi’s teplizumab, which is already FDA-approved to delay the onset of stage 3 type 1 diabetes, has been included on the list. The agency said it was selected for “type 1 diabetes,” hinting that the review could be for a broader label approval. Revolution Therapeutics’ RMC-6236, in development for the treatment of pancreatic cancer, and Disc Medicine’s porphyria therapy bitopertin round off the list of products for specific diseases. The FDA selected cytisinicline for nicotine vaping addiction, while ketamine and Augmentin XR were chosen to boost domestic manufacturing of anaesthesia and antibiotics, respectively. The CNPV programme is the latest move by the Trump administration to bolster its pharmaceutical armoury and incentivise the development of new drugs specifically for Americans . Pharma companies wishing to reap the benefits of the programme need to demonstrate US-centric potential for their drug candidates. Therapies need to address a health crisis in the country, produce an innovative cure for American patients, meet public health needs, or increase domestic drug manufacturing as a national security issue. In its statement sharing the first batch of recipients, the FDA said that each product has significant potential to address one or more of these major national priorities. The agency stated that it would likely add another group of CNPV recipients in the coming months. Companies with a product in the programme will receive a decision within 1-2 months, compared to the usual 10-12 months, following filing of a complete application for a drug or biologic. Sponsors will also be able to undertake enhanced feedback with FDA staff during development and the review window. “One of our core goals is to deliver more cures and meaningful treatments – especially ones that have an outsized impact on our most pressing national priorities. We must modernise the review process and try new approaches to meet the needs of the American people,” said FDA commissioner Marty Makary. While the CNPV pilot begins its journey in the US regulatory landscape, experts have been concerned that its activity could take attention away from similar programmes that incentivise rare diseases. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

Drug ApprovalPriority Review

17 Oct 2025

·www.fiercebiotech.com

FDA names 9 first recipients of 1- to 2-month priority review vouchers

Revolution Medicines and Disc Medicine are among the recipients of a Commissioner’s National Priority Voucher. \n The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and Sanofi to complete the approval process in one to two months.FDA Commissioner Marty Makary, M.D., launched the program in June, and the agency began accepting applications in July. The program is designed to cut product approval times, which are typically 10 to 12 months, for medicines that align with U.S. national priorities. Specific priorities include addressing the U.S. public health crisis, treating large unmet medical needs and delivering transformative treatments.The first nine recipients of a Commissioner’s National Priority Voucher (CNPV) are a mix of approved drugs and investigational medicines. The investigational products include DB-OTO, the gene therapy that Regeneron is developing to treat a rare genetic form of hearing loss. Regeneron plans to seek FDA approval this year. If the CNPV works as intended, the timeline suggests the gene therapy could come to market early next year at the latest. The company has published data on the gene therapy in 12 patients, nine of whom only received the treatment in one ear. Talking on an FDA podcast, Mallika Mundkur, M.D., who leads the CNPV program at the agency, said the DB-OTO data are “pretty remarkable” but cautioned that “we need to learn more about” its safety. The podcast was hosted by Makary, who said the hearing restoration data point to the need for the FDA “to get a decision out promptly using the standard scientific process, cutting any wasted time.” Makary added that “we\'re hearing the company may make it available either at an extremely low price or for free, which of course is part of a national priority to make drugs more affordable.” The criteria for the CNPV program include lowering the U.S. price of a drug consistent with most-favored nation pricing.Revolution Medicines’ RMC-6236 and Disc Medicine’s bitopertin are among the other recipients of a CNPV. RMC-6236, also called daraxonrasib, is a RAS-MULTI(ON) inhibitor that is in phase 3 development as a treatment for forms of pancreatic and non-small cell lung cancer. Data from one of the trials are due next year. Revolution is holding off on adjusting its timelines while it assesses the impact of the voucher.Discussing RMC-6236 on the podcast, Makary said the FDA’s oncology division “thought this is something that is potentially promising.” The FDA commissioner went on to say the agency is going into its divisions and asking reviewers what programs they think “may potentially look amazing.” Makary framed the talks as a push for the FDA to move beyond “receive-only mode” when identifying assets it can accelerate. Meanwhile, Disc\'s bitopertin is a GlyT1 inhibitor being assessed in rare, genetically driven hematologic diseases. The biotech filed for accelerated FDA approval of the small molecule last month. Disc originally applied for a priority review that would reduce the review time from 10 months to six months. The FDA also awarded CNPVs to Merck’s pergoveris and Sanofi’s teplizumab. Pergoveris, a fertility drug, is already available in 74 countries. Merck plans to file for FDA approval of the drug using its CNPV, which it disclosed as part of a broader deal with the U.S. government to expand access to fertility treatment. Teplizumab, which Sanofi sells as Tzield, is FDA-approved to delay the onset of forms of Type 1 diabetes.Officials gave another two CNPVs to cytisinicline for nicotine vaping addiction and cenegermin-bkbj for blindness. Achieve Life Sciences is seeking approval of cytisinicline for smoking cessation. Cenegermin is already sold as Oxervate by Dompé Farmaceutici to treat a corneal disease. The final two CNPVs are focused on onshoring, with the FDA using the vouchers to try to boost domestic production of ketamine for general anesthesia and of the antibiotic augmentin XR. Phlow received the ketamine CNPV.

Phase 3Priority ReviewDrug Approval

17 Oct 2025

·firstwordpharma.com

TrumpRx welcomes Merck KgaA, one of nine to receive new priority voucher

Merck KGaA is the latest drugmaker to slash some of its products' US list prices in exchange for an exemption from President Donald Trump's 100% pharmaceutical tariff — and one of the first to receive a new kind of speedy review voucher from the FDA.The third pharma to reach a most-favoured nation (MFN) drug pricing deal with the Trump administration, Merck — through its US-based healthcare business unit, EMD Serono — will make its in vitro fertilization (IVF) therapies available through a direct-to-consumer (DTC) platform that patients with prescriptions will be able to reach via the government-run TrumpRx website, due to launch in January. The company said on Thursday that if all three of its IVF offerings — Gonal-f (follitropin alfa injection), Ovidrel (choriogonadotropin alfa injection) and Cetrotide (cetrorelix acetate for injection) — are used in a single IVF protocol, patients will pay 84% less than the total list price. While AstraZeneca's and Pfizer's respective MFN deals earned them each a three-year grace period from tariffs, Merck said in a release that its pharmaceutical products and ingredients will be excluded from tariffs, without a time limit, "provided EMD Serono invests in future biopharmaceutical manufacturing and research in the United States."The German drugmaker "look[s] forward to growing our footprint here even further with future fertility manufacturing," said Belén Garijo, CEO and chair of Merck, in a company release.A new kind of priority reviewAnd more fertility options for US patients are on the way. In conjunction with the MFN deal, Merck also announced that it's part of the inaugural cohort of companies to receive one of the FDA's new Commissioner’s National Priority Vouchers (CNPVs). The pharma plans to use its voucher to accelerate review of Pergoveris, an IVF therapy that combines recombinant human follicle stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) in a single injection pen. The product has been approved in Europe since 2017. With the CNPV, Merck is promised a regulatory decision on Pergoveris within one to two months after filing the application, along with "enhanced" communication with FDA staff during the review process. The US regulator had said in June it planned to start handing out CNPVs to drugmakers "addressing our most important US national priorities," either by attempting to solve a health crisis, upping domestic manufacturing or developing an innovative treatment. In July, FDA Commissioner Marty Makary suggested that companies that promise to "equalise" the cost of their drugs between the US and other countries could also qualify for a CNPV.In addition to Merck's Pergoveris, the FDA on Thursday revealed eight other products that have earned a CNPV, including Regeneron's hearing loss gene therapy DB-OTO; the company had announced plans to file for FDA approval of the one-time treatment just days earlier.Another CNPV went to Sanofi's anti-CD38 antibody teplizumab to treat type 1 diabetes. Initially approved by the FDA in 2022 to delay the onset of stage 3 type 1 diabetes in adults and children aged 8 years and older who have stage 2 disease, the French pharma gained teplizumab through its $2.9-billion takeout of Provention Bio in 2023.Revolution Medicines has snagged a voucher for pancreatic cancer treatment daraxonrasib (RMC-6236); it started a registrational trial of the pan-RAS inhibitor in October 2024. Disc Medicines will get a fast review for bitopertin, having just submitted an application on Sept. 30 for the oral GlyT1 inhibitor to treat erythropoietic protoporphyria, including X-linked protoporphyria.FDA approved for neurotrophic keratitis in 2018, Dompé Farmaceutici's cenegermin received a voucher for blindness. Other recipients include Achieve Life Sciences' nicotine vaping addiction treatment cytisinicline, as well as domestically manufactured versions of ketamine and Augmentin XR, an antibiotic.

Drug ApprovalPriority Review

100 Deals associated with Cenegermin-BKBJ

External Link

KEGG	Wiki	ATC	Drug Bank
-	Cenegermin-BKBJ	S01XA24	DB13926

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Neurotrophic keratitis	European Union	Dompe Farmaceutici SpA	06 Jul 2017
Neurotrophic keratitis	Iceland	Dompe Farmaceutici SpA	06 Jul 2017
Neurotrophic keratitis	Liechtenstein	Dompe Farmaceutici SpA	06 Jul 2017
Neurotrophic keratitis	Norway	Dompe Farmaceutici SpA	06 Jul 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dry Eye Syndromes	Phase 3	United States	Dompe Farmaceutici SpA	19 Jan 2022
Dry Eye Syndromes	Phase 3	Italy	Dompe Farmaceutici SpA	19 Jan 2022
Sjogren's Syndrome	Phase 3	United States	Dompe Farmaceutici SpA	19 Jan 2022
Sjogren's Syndrome	Phase 3	Italy	Dompe Farmaceutici SpA	19 Jan 2022
Kerato conjunctivitis sicca	Phase 2	United States	Dompe Farmaceutici SpA	20 Jan 2017
Cataract	Phase 2	Italy	Dompe Farmaceutici SpA	12 Jan 2017
Blindness	Phase 2	Italy	Dompe Farmaceutici SpA	01 May 2015
Macular Edema	Phase 2	Italy	Dompe Farmaceutici SpA	01 May 2015
Retinitis Pigmentosa	Phase 2	Italy	Dompe Farmaceutici SpA	01 May 2015
Corneal Ulcer	Phase 2	France	Dompe Farmaceutici SpA	01 Jan 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03982368 (Pubmed) Manual	Phase 2	Dry Eye Syndromes	-	Cenegermin 20 mcg/mL t.i.d.	pgerbeufdq(tbxzudlbea) = smvnzlmvmd bgbvqjtces (cguqtibjhl ) View more	Negative	17 Jul 2024
				Cenegermin 20 mcg/mL b.i.d.	pgerbeufdq(tbxzudlbea) = iqcklvptgd bgbvqjtces (cguqtibjhl ) View more
NCT04485546 (DEFENDO, Pubmed)	Phase 4	Neurotrophic keratitis	37	Cenegermin 20 mcg/ml	nxymgzujnt(wwahsyktfo) = aqoolwpfir ijhzpgfniu (naphekwwsb, 5.1 - 31.9) View more	-	01 Feb 2024
NCT04485546 (DEFENDO, CTgov)	Phase 4	Neurotrophic keratitis	37	cenegermin-bkbj	cetuucfzva = tjprehpqhx fnmlznltvc (cisphhmcgl, tpiqcobngz - ygnozhgnlx) View more	-	23 Jun 2023
NCT04552730 (Pubmed \| Ther Adv Ophthalmol)	Not Applicable	Limbal stem cell deficiency	5	Cenegermin	bmhosfhkzv(sgmcnsllyd) = phaisrxtuv yjkkmzskvm (oikigqihcw ) View more	-	01 Jan 2022
NCT02855450 (NGF-Glaucoma, CTgov)	Phase 1	Glaucoma	60	rhNGF (rhNGF)	awsuwuepfq = yingkmvght nqqvbajocb (mfrskqpong, focuvtiorq - wsthuwrmsi) View more	-	25 Nov 2020
				Vehicle (Vehicle)	awsuwuepfq = jsfjexdund nqqvbajocb (mfrskqpong, qaaubxsoho - dswypwaimu) View more
NCT03836859 (CTgov)	Phase 1	-	30	rhNGF 20μg/mL (rhNGF 20μg/mL)	vmidplfnvx = xosflkhczr bkcvflapxb (eaffmsqdig, guythmvuks - wtkybnfsjs) View more	-	11 Jun 2020
				Placebo (Placebo)	vmidplfnvx = sjlcnmides bkcvflapxb (eaffmsqdig, btggovrwrk - gdsxkgeggn) View more
NCT02101281 (Pubmed \| Br J Ophthalmol) Manual	Phase 2	Dry Eye Syndromes	40	rhNGF (20 µg/mL)	ijhnfrykqc(dybytsshzu) = npmjuxhelp tjqzmknscu (pfbdmxuepi, 26.2) View more	Positive	01 Jan 2020
				rhNGF (40 µg/mL)	ijhnfrykqc(dybytsshzu) = eoikelkeqc tjqzmknscu (pfbdmxuepi, 26.4) View more
NCT02101281 (CTgov)	Phase 2	Dry Eye Syndromes	40	rhNGF 20 µg/mL (Group 1 - rhNGF 20 μg/mL)	hffjefuhnd = mmnrddytjz iyaxrkcpeq (qoeerzfzib, xnxfwspprs - wrrjrxvipj) View more	-	07 Aug 2019
				rhNGF 4 µg/mL (Group 2 - rhNGF 4 μg/mL)	hffjefuhnd = ewhkkbyjpz iyaxrkcpeq (qoeerzfzib, kmarntyeko - efsxqpsbxs) View more
NCT03035864 (CTgov)	Phase 2	Cataract	180	rhNGF (rhNGF 20 µg/ml)	uecokkokba(ptmlwsplvi) = edxgkkqxsb vscjvlrgyt (wljaajnblf, 24.85) View more	-	22 Jul 2019
				Vehicle (Vehicle)	uecokkokba(ptmlwsplvi) = ucdvayflmw vscjvlrgyt (wljaajnblf, 26.04) View more
NCT02110225 (Lumos, CTgov)	Phase 1/2	Retinitis Pigmentosa	50	rhNGF 60 µg/ml eye drops solution (rhNGF 60µg/ml)	ydsxikfnmf = krfifvlwvc cmhzuqsbty (xtwggeepxt, gfrgpzglnb - onngzycofz) View more	-	11 Jul 2019
				rhNGF (rhNGF 180 µg/ml)	ydsxikfnmf = kfurgfrvrb cmhzuqsbty (xtwggeepxt, wspuwczpdg - gxenyihajp) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis